Aberrant expression of microRNAs (miRNAs) has been implicated in cancer initiation and progression. However, little is known about the potential role of miRNAs in glioma tumorigenesis. In this study, we found that miRNA-106b-5p was significantly upregulated in glioma tumor samples and cell lines compared with normal brain tissues, and its expression level correlated with the pathological grading. Overexpression of miR-106b-5p in glioma tumor cells significantly promoted cell proliferation, although inhibited cell apoptosis in vitro and in vivo. In contrast, knockdown of miR-106b-5p significantly inhibited cell proliferation, although enhanced cell apoptosis. Mechanistic study revealed that two target genes, retinoblastoma-like 1 (RBL1) and RBL2, were involved in miR-106b-5p's regulation of cell proliferation and one target gene, caspase-8 (CASP8), mediated miR-106b-5p's regulation of apoptosis. We also investigated the function of the three targets in glioma tumorigenesis by RNA interference manipulation and demonstrated that knockdown of these target genes led to cell proliferation enhancement or cell apoptosis inhibition in vitro. More interestingly, the expression levels of these targets were significantly downregulated in glioma samples and knockdown of these targets in glioma cells inhibited the xenograft tumor formation in vivo. Moreover, we verified the regulation function of miR-106b-5p and its targets on cell proliferation and apoptosis of the primary cultured astrocytes isolated from glioma tumor samples and healthy controls. Collectively, our findings show the critical roles of miR-106b-5p and its targets, RBL1, RBL2 and CASP8, in glioma tumorigenesis and provide potential candidates for malignant glioma therapy.
INTRODUCTION
Gliomas are the most common central nervous system tumors in adults with an incidence of B5 cases per 100 000 persons. They are histologically classified as astrocytomas, oligodendrogliomas and oligoastrocytomas and are graded I À IV on the WHO (World Health Organization) grading system according to their degree of malignancy. 1 Because of our poor understanding of this cancer's pathogenesis, therapeutic strategies for glioma are limited. 2 Despite the most advanced treatment with combinations of surgery, radiotherapy and chemotherapy, glioblastoma multiforme, the most malignant and most common glioma, is associated with an average life expectancy of only 14 months. 3 Studying the molecular implications of genetic alterations underlying the glioma should aid in the development of new diagnostic, prognostic and therapeutic approaches. Over the past 20 years, genetic, cell biological and animal modeling studies have implicated a number of proteincoding genes in the formation and progression of malignant gliomas; however, the function of non-coding RNAs including microRNA (miRNA) in glioma pathogenesis remained largely unknown.
MiRNAs represent a large family of short non-coding endogenous RNAs that posttranscriptionally regulate the expression of protein-coding genes by binding to the specific binding sites in their 3 0 -terminal untranslated regions (3 0 -UTR) and finally lead to mRNA degradation or translation termination. Previous studies have demonstrated that miRNAs have important roles in a wide variety of physiological and pathological processes including cancer. 4 They are aberrantly expressed in many cancers and can exert tumor suppressive or oncogenic functions by regulating the target expressions. 5 Aberrant expression of miRNAs in gliomas has also been reported, and several miRNAs (such as miR-21, miR-221/ 222, miR-181 and so on) have been functionally involved in glioma pathogenesis. 6 These findings indicated that miRNAs may act as another kind of important regulators in glioma tumorigenesis in addition to the protein-coding genes.
miR-106b-5p was reported as an oncogenic miRNA involved in many tumor types, such as gastric cancer, hepatocellular carcinoma, laryngeal carcinoma, prostate cancer, breast cancer and so on. [7] [8] [9] [10] [11] However, the function of miR-106b-5p in glioma tumorigenesis is still unknown. Here, we reported that miR-106b-5p is critical in regulating glioma cell proliferation and apoptosis and boosts glioma tumorigenesis. Moreover, miR-106b-5p was aberrantly upregulated in glioma samples and cell lines, boosted cell proliferation and inhibited cell apoptosis in glioma cells both in vitro and in vivo. Mechanistic study revealed that miR-106b-5p regulated glioma tumorigenesis through regulating the targets of retinoblastoma-like 1 (RBL1), RBL2 and CASP8.
RESULTS
MiR-106b-5p was overexpressed in human glioma tumor samples and cell lines To search for miRNAs potentially involved in glioma tumorigenesis, we first profiled miRNA expression in glioma tumor samples and healthy controls using the microarray technique. Our analysis showed that a total of 29 human miRNAs were differentially expressed with a greater than 10-fold change in glioma samples compared with healthy controls (Figure 1a) . The expression levels of four miRNAs (miR-21, miR-10b, miR-210 and miR-26a) were all upregulated in glioma tumor samples compared with healthy controls, in keeping with the previous profiling study, which was confirmed by other independent reports. 6, 12 Among them, miR106b-5p showed a 20-fold upregulation in glioma tumor samples (Figure 1b) . To verify the upregulation of miR-106b-5p, we performed northern blot and real-time quantitative PCR (QPCR) analyses, and data from northern blot analysis showed obvious increase in miR-106b-5p expression in the glioma samples compared with that in healthy controls (Figure 1c and Supplementary Table S1 ). QPCR data also showed a 10-fold upregulation of miR-106b-5p in glioma samples (Figure 1d ). To explore whether there is any association between the upregulation of miR-106b-5p and the pathogenesis of glioma, we detected the expression of miR-106b-5p in glioma tumor samples with different disease severity according to the WHO grades 1 and found an eightfold increase in the grade I or II glioma samples, whereas a much more 14-fold increase was observed in the later grade III or IV glioma samples, which gave some clues that miR106b-5p may be involved in the disease pathogenesis in glioma (Figure 1e ). To further investigate the association between miR-106b-5p expression and glioma tumorigenesis, we examined miR-106b-5p expression in several glioma tumor cell lines using QPCR. The data showed that miR-106b-5p expression was substantially increased in all the cell lines derived from glioma tumors, compared with the normal brain tissues (Figure 1f) . Thus, these data suggest that miR-106b-5p is upregulated in gliomas and its expression level positively correlated with disease severity.
MiR-106b-5p boosted glioma tumor proliferation To explore the role of miR-106b-5p in glioma tumorigenesis, we examined the effect of miR-106b-5p overexpression on the proliferation of U87 and LN-229 glioma cell lines. The cells were transfected with miR-106b-5p mimics (miR-106b), antisense miR106b-5p or scramble control oligonucleotides. Northern blot and QPCR analyses showed that mature miR-106b-5p was significantly increased in cells transfected with miR-106b-5p mimics and decreased in the antisense miR-106b-5p-transfected group compared with the scramble control (Figures 2a and b) . The MTT assay showed that the overexpression of miR-106b-5p significantly boosted the proliferation of both U87 and LN-229 cells, whereas the knockdown of miR-106b-5p inhibited cell growth in both cell lines (Figures 2c and d) . The clone formation assay was performed to further confirm the effect of miR-106b-5p on glioma cell proliferation, and data indicated that overexpression of miR-106b-5p significantly increased clone numbers in U87 and LN-299 cell cultures, whereas knockdown of miR-106b-5p expression obviously decreased clone formation. Further study were performed in the other three glioma cell lines (U251, A172 and T98G), and we observed the similar phenomenon that miR106b-5p can boost cell proliferation in these cell lines (Supplementary Figure S2) . Collectively, these results indicate that miR-106b-5p may have a role in controlling glioma cell proliferation.
MiR-106b-5p inhibited glioma cell apoptosis As previous demonstrated, cell apoptosis is another important cell mechanism involved in glioma tumorigenesis. 13 Thus, we further investigated the effect of miR-106b-5p on glioma cell apoptosis. As shown in Figure 3 , serum deprivation can induce 30% of cell apoptosis in U87 glioma cell lines, and only 15% of cell apoptosis was observed in the U87 cells with an overexpressed level of miR-106b-5p; however, more than 60% of cell apoptosis was detected when we knocked down the miR-106b-5p in the U87 cell (Figures 3a and b) . Similar results were also observed in the LN-229 glioma cell line, overexpression of miR-106b-5p significantly inhibited the serum deprivation-induced apoptosis of LN-229 cells, whereas the knockdown of miR-106b-5p remarkably promoted cell apoptosis in LN-229 cell line (Figures 3c and d) . These results support that miR106b-5p also has a role in controlling cell apoptosis of glioma cells.
RBL1, RBL2 and CASP8 served as the functional targets of miR-106b-5p To explore the potential target genes of miR-106b-5p in glioma tumorigenesis, we used miRanda, miRDB and DIANA-microT-CDS algorithms to search for putative human protein-coding gene targets of miR-106b-5p. [14] [15] [16] The genes for RBL1, RBL2 and CASP8 were predicted to have putative miR-106b-5p-binding elements in their 3 0 -UTRs with high-fidelity scores (Figure 4a ). Overexpression of miR-106b-5p or knockdown of miR-106b-5p in U87 cells greatly changed the protein levels of RBL1, RBL2 and CASP8, whereas their mRNA expression levels were not significantly affected (Figures 4b and c) , and the regulation of these target protein expression by mir-106b-5p was also observed in other glioma cell lines (Supplementary Figure S3) ; these data suggest that miR106b-5p may suppress the expression of the target genes through translational repression. To test whether the predicted miR-106b-5p-binding sites in the 3 0 -UTR of the three target genes were responsible for miR-106b-5p regulation, we cloned their WT or mutated 3 0 -UTR region downstream of a luciferase reporter gene and co-transfected these vectors together with miR-106b-5p mimics or its scramble control into 293T cells. The luciferase activity of cells transfected with miR-106b-5p mimics was significantly decreased compared with the scramble controls (Figures 4d-f) . However, the mutation of the putative miR-106b-5p-binding sites in 3 0 -UTR region clearly abrogated the repression of the luciferase activity caused by miR-106b-5p overexpression (Figures 4d-f ). To further investigate whether miR-106b-5p regulated these targets in vivo, the protein expression levels of RBL1, RBL2 and CASP8 were tested by western blot using specific antibodies, and the results indicated that the protein expression levels of the three targets were significantly downregulated in gliomas samples compared with healthy controls, and, at the same time, the miR-106b-5p expression was upregulated in the 
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RBL1, RBL2 and CASP8 were involved in miR-106b-5p's regulation of glioma tumorigenesis As miR-106b-5p regulates glioma cell proliferation/apoptosis and suppresses RBL1, RBL2 and CASP8 protein expression, we are interested in examining whether miR-106b-5p has a role in the regulation of cell proliferation/apoptosis via these target regulations. To verify this hypothesis, we used gene-specific siRNA; 17, 18 first of all, we checked the RNA interference (RNAi) efficiencies of these siRNAs by transfecting them into the glioma cell line U87 cells, and both western blot and QPCR analyses showed that all of the three siRNAs can significantly knock down the targets relatively (Figures 5a and b) . Data from the MTT assay showed that when we knocked down the expression of RBL1 or RBL2 in U87 cells, cell proliferation was significantly enhanced compared with the scramble control; however, the siRNA of CASP8 seemed to have little influence on U87 proliferation ( Figure 5c ). The results from the clone formation assay verified the MTT results, and the finding that siRNAs of RBL1 or RBL2 can promote clone formation in U87 cells, whereas the siRNA of CASP8 was found to have little effect on clone formation in U87 (Figures 5d and e) . We further investigated their role in cell apoptosis, and we found that only the siRNA of CASP8 can inhibit serum deprivation-induced apoptosis in U87 cells, which almost mimics the effects of overexpression of miR-106b-5p. Meanwhile, we observed no significant effect on U87 apoptosis when we knocked down the expression of RBL1 or RBL2 (Figures 5f and g ). These data suggest that the three targets mediated different functions of miR-106b-5p in glioma tumorigenesis, in which RBL1 and RBL2 may mediate miR-106b-5p's regulation of cell proliferation and CASP8 may mediate its regulation on cell apoptosis.
Increased miR-106b-5p expression suppresses xenograft tumor formation To further evaluate the potential effect of miR-106b-5p on glioma tumorigenesis in vivo, we constructed several recombinant retroviruses, which overexpress miR-106b-5p precursor, shRNA of target genes (RBL1, RBL2 and CASP8) and the scramble control. Data from QPCR demonstrated that these viruses can efficiently mediate miR-106b-5p overexpression or knockdown of the target genes ( Figure 6a ). After stable transfection by these viruses, U87 cells were subcutaneously inoculated into each athymic nude mice with scramble in the left side and the miR-106b-5p or shRNA in the right side. Forty-two days after inoculation, the mean volume of the xenograft tumor in miR-106b-5p overexpression group was significantly bigger than that in the scramble control (Figures 6b and c) . We were also interested in whether the target genes were also involved in miR-106b-5p's regulation of glioma tumorigenesis in vivo, and thus we also analyzed the shRNAs of virus-transfected U87 cells with the xenograft tumor formation assay, and the results showed that the knockdown of any one of the three target genes can significantly boost tumorigenesis, which can mimic the effects of miR-106b-5p (Figure 6d ). However, we observed that the overexpression of miR-106b-5p showed the strongest effects, which might be due to fact that the effects of miR-106b-5p overexpression are mediated by the regulation of the three targets at the same time. Thus, these data indicate that miR-106b-5p may promote xenograft tumor formation of glioma tumor cells in vivo. In order to investigate whether the three target genes mediated miR-106b-5p's regulation on tumor growth in vivo, miR-106b-5p was overexpressed alone or together with the open reading frames (ORFs) of the three target genes by lentivirus infection in U87 cells, and then the infected cells were subcutaneously inoculated into nude mice shown in Figure 6e , respectively. As they do not carry any miR-106b-5p-targeting sites, the target genes' ORFs will not be regulated by miR-106b-5p, the tumor sizes showed in Figure 6e indicated that miR-106b-5p overexpression still can boost tumor growth in vivo compared with the scramble control; however, only one target ORF alone cannot rescue the phenotype caused by miR-106b-5p overexpression, whereas the three targets together can obviously rescue the phenotype caused by miR-106b-5p. At the same time, we detected the targets' protein level at day 42 in the end of the experiments, and data in Figure 6f indicated that lentiviruses successfully mediated the overexpression of RBL1, RBL2 and CASP8 in the relative groups. These observations demonstrated the functional relevance of the reported target genes of miRNA106b-5p in tumor regulation.
Regulation of cell proliferation and apoptosis in primary cultured astrocytes isolated from healthy control or glioma patients by miR-106b-5p and its targets Although the above data demonstrated the regulation of cell proliferation and apoptosis in glioma cell lines by miR-106b-5p and its target genes, we were curious whether miR-106b-5p and its targets can regulate the primary isolated astrocytes from glioma patients or healthy controls. As the glial fibrillary acidic protein (GFAP) is the specific marker protein expressed by astrocytes, so we identified the isolated primary cultured astrocytes by GFAP antibody staining, and the results showed that most of the isolated cells expressed GFAP in the primary culture of ascroctyes from both healthy controls and glioma patients (Figure 7a ). We also quantitated the expression level of miR-106b-5p in these astrocytes and found a significant upregulation of miR-106b-5p in the astrocytes from glioma patients compared with healthy controls (Supplementary Figure S1) . Thereafter, the astrocytes from healthy controls were infected with viruses overexpressing miR-106b-5p or shRNAs of its targets genes, and the results showed that the expression levels of the three target genes were all decreased in miR-106b-5p-overexpressed astrocytes, and the shRNAs of three target genes could knock down the targets specifically as predicted (Figure 7b ). Proliferation analysis indicated that the overexpression of miR106b-5p significantly enhanced cell proliferation (Figure 7c , the second bar), and the knockdown of the RBL1 or RBL2 also promoted cell proliferation (Figure 7c the third to fourth bar) . However, the knockdown of CASP8 had little effect on cell proliferation (Figure 7c the fifth bar) . Further, apoptosis analysis showed that the overexpression of miR-106b-5p could significantly inhibit serum starvation-induced apoptosis, and, among the three targets, only knockdown of CASP8 could mimic this effect (Figure 7d ). We further analyzed astrocytes from glioma patients, and the results showed that inhibition of miR-106b-5p with a specific sponge increased the target expression, inhibited cell proliferation and enhanced serum starvation-induced apoptosis (Figure 7e -g, the second lane or bar), whereas the overexpression of RBL1 or RBL2 could mimic miR-106b-5p's regulation on cell proliferation but not regulation on apoptosis (Figure 7f -g, the third and fourth bar). However, the overexpression of CASP8 could mimic miR-106b-5p's regulation on apoptosis but not on proliferation (Figure 7f -g, the fifth bar). All these data indicated that miR-106b-5p enhanced cell proliferation and inhibited apoptosis in primary cultured astrocytes, which is probably through the regulation of the three target genes relatively.
DISCUSSION
MiR-106b-5p is one of the most overexpressed miRNAs in a number of profiling experiments designed for the detection of miRNAs dysregulated in human cancers. [7] [8] [9] 11 In 2008, Ambs et al. 19 reported that miR-106b-5p was significantly upregulated in human prostate tumor compared with non-tumor prostate tissues. The present profile data further confirmed an increased expression of miR-106b-5p both in glioma tumors and in cell lines. The miR-106b-5p expression status was further validated using QPCR in all 10 glioma cell lines. Although glioma cell lines have extremely diverse genetic background, universal overexpression of miR-106b-5p in both glioma tumors and cell lines indicates that miR-106b-5p has a robust role in glioma cell cancerous transformation.
Generally, miRNAs are believed to function in vivo by targeting protein-coding genes by binding to the characteristic binding sites in the targets' 3 0 -UTRs. On the basis of this principle, several computational algorithms can predict hundreds of mRNAs as possible targets for miR-106b-5p [14] [15] [16] . Among these predicted targets, several genes have been experimentally validated. E2F1 and p21 were the most frequently reported targets, 9, [19] [20] [21] [22] and TbetaR II was reported to mediate miR-106b-5p's regulation of AD pathogenesis. 23 Caspase-7 was identified as the miR-106b-5p target during prostate cancer progression. 24 Recently, two new miR-106b-5p targets have been reported, including RB in laryngeal carcinoma cell proliferation and ULK1 in autophage regulation. 7, 25 Wang et al. 26 have reported that miR-106b-5p was upregulated in the pediatric brainstem gliomas; however, the function and the target gene of miR-106b-5p in glioma tumorigenesis are still unknown. Here we demonstrated that miR-106b-5p acts as an oncogenic miRNA in glioma tumorigenesis. In addition, we also indentified miR-106b-5p targets including RBL1 and RBL2, which mediated miR-106b-5p's regulation on glioma cell proliferation. A previous study also reported miR-106b-5p's regulation on the RBL1/RBL2 3 0 -UTR reporter activity; 27 however, the endogenous regulation of the RBL1/RBL2 protein level is unclear. Here we showed that miR-106b-5p actually regulates RBL1/RBL2 protein expression both in vitro and in vivo. More interestingly, we also found that RBL1/RBL2 themselves can act as the tumor suppressors in regulating glioma tumorigenesis by gene knockdown in both in vitro cell proliferation assay and in vivo xenograft tumor formation assay. In addition to excessive proliferation of tumor cells, the strong resistance to apoptosis is another common characteristic of tumor cells. 13 Our data showed that the overexpression of miR-106b-5p enhanced the resistance to serum deprivation-induced apoptosis in glioma cells, and, more interestingly, miR-106b-5p regulated this process through another new target, CASP8, which is one of the important components in caspase-mediated cell apoptosis. 28 Further, we also demonstrated that CASP8 is involved in glioma tumorigenesis applying CASP8-specific RNAi analysis.
As RBL1, RBL2 and CASP8 were identified as miR-106b-5p targets in glioma, their roles in glioma tumorigenesis need further illustration. Here, we verified their roles as tumor suppressors in gliomas tumorigenesis at least in the xenograft tumor assay by direct gene manipulation. By analyzing their expression in glioma samples and the healthy controls, we found that they were all downregulated in tumor samples, and the downregulation of CASP8 in gliomas was consistent with that previously reported. 28 When combined, the findings that the upregulation of miR-106b-5p and the regulation of the three targets in gliomas may suggest that the miRNA-protein pairs may serve as potential therapeutic targets for glioma therapy in the future.
In summary, we found that miR-106b-5p was significantly upregulated in gliomas and acted as an oncogene and regulated the glioma cell proliferation and apoptosis both in vitro and in vivo. Moreover, two target genes, RBL1 and RBL2, were identified as involved in the miR-106b-5p's regulation of glioma cell proliferation, and one target gene, CASP8, mediated miR106b-5p's regulation of glioma cell apoptosis. In addition, these three targets were all downregulated in gliomas and they acted as tumor suppressors. Our findings show the critical roles of miR106b-5p and its targets, RBL1, RBL2 and CASP8, in glioma tumorigenesis and provide potential candidates for malignant glioma therapy. Figure 6 . Overexpression of miR-106b-5p or knockdown of three targets enhanced xenograft tumor growth. U87 cells with stably overexpressed miR-106b-5p, overexpression or knockdown target genes were injected subcutaneously into nude mice, respectively. Forty-two days after injection, U87 cell xenografts in scrambles or miR-106b-5p treatments were dissected and the photographs were taken before surgery. (a) QPCR analysis of miR-106b-5p overexpression or the target knockdown efficiencies in the tumors mediated by the viruses. (b) Tumor volumes were measured in the miR-106b-5p overexpression group or the scramble group. (c) The mouse with tumor in (b) is represented. (d, e) During the tumor growth, the tumor sizes in scramble, miR-106b-5p overexpression or target RNAi groups (d) and in scramble, miR-106b-5p overexpression or target ORFs overexpression groups were measured (e) every 7 days and the tumor volume growth curve is drafted. (f ) The protein expression levels of RBL1, RBL2 and CASP8 were tested in the tumor tissues at day 42 in the end of these experiments. **Po0.01, ***Po0.001 versus scramble control (Student's t-test).
MATERIALS AND METHODS
Cell culture, synthetic RNA oligos and transfection Glioma cell lines (H4, A172, LN-308, U251, LN-229, LN-428 , U373, U138, U87 and T98G) and the 293T cell lines were maintained in the Dulbecco's modified Eagle's medium (DMEM; Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (Invitrogen), 2 mM glutamine (Sigma), 100 units of penicillin/ml (Sigma, St Louis, MO, USA) and 100 mg of streptomycin/ml (Sigma), at 37 1C with 5% CO 2 . The primary human astrocytes were isolated and cultured as previously described. 29 The miR106b-5p mimics (miR-106b), antisense miR-106b-5p inhibitor, siRNA against human RBL1, RBL2, 17 CASP8 18 and the relative negative scramble control RNA oligos composed of 21 randomized base pairs with no significant similarity to human genome DNA by BLAST search (Scramble) were synthesized by Shanghai Gene-Pharma Co. All RNA transfections were performed at a final concentration of 50 nM, using Lipofectamine 2000 (Invitrogen). The sequences of the RNA oligos were shown in Supplementary Table S2.
Patients and tissue samples
Tissue samples from normal brain tissues and human glioma tumors were collected from the neurosurgery department of Changzhou NO.2 People's Hospital (Changzhou, China). Samples were collected and snap-frozen in liquid nitrogen immediately and preserved in À 80 1C until use, and their histological type was further confirmed using the standard hematoxylin and eosin staining according to the WHO criteria. A total of 45 samples were used for this study including primary-grade pilocytic astrocytomas or grade II astrocytomas (WHO I/II, n ¼ 12), grade III anaplastic astrocytomas or grade IV glioblastoma multiforme (WHO III/IV, n ¼ 13) and normal brain tissues derived from the temporal lobes and saddle area of the patients with arachnoid cyst after surgery (n ¼ 20), both glioma patients and controls have the similar percentages with respect to sex and age. This study was approved by the Research Ethnics Committee of Changzhou NO.2 People's Hospital. Informed consent was obtained from all patients.
Plasmid construction and retrovirus preparation
For miR-106b-5p overexpression, a genomic sequence spanning the human pre-miR-106b-5p-coding region was cloned into the pRetro-Super vector, at the downstream of H1 promoter. 30 For miR-106b-5p inhibition, the specific sponge 31 (three sponge repeats) was cloned into the same vector. For target gene knockdown, the shRNAs with the same target site to siRNAs against human RBL1, RBL2 and CASP8 were cloned into the Figure 7 . Regulation of cell proliferation and apoptosis in primary cultured astrocytes isolated from healthy control or glioma patients by miR106b-5p and its targets. Primary cultured astrocytes were isolated from healthy control or glioma patients, after virus-mediated manipulation of miR-106b-5p, and its targets expression, cell proliferation in 3 days were analyzed using the MTS assay and serum starvation-induced apoptosis was analyzed by Annexin V/Propidium Iodide staining. (a) Identification of the primary cultured human astrocytes with a specific marker GFAP antibody. (b-d) The astrocytes from healthy controls were infected with viruses expressing the scramble control, miR-106b-5p, RBL1 shRNA, RBL2 shRNA and CASP8 shRNA relatively; the protein level of three targets genes (b), cell proliferation rate in 3 days (c) and serum starvation-induced apoptosis (d) were shown. (e-g) The astrocytes from glioma patients were infected with viruses expressing the scramble control, miR-106b-5p inhibitor (sponge-106b), RBL1, RBL2 and CASP8 protein relatively; the protein level of three targets genes (e), cell proliferation rate in 3 days (f ) and serum starvation-induced apoptosis (g) were shown. *Po0.05, **Po0.01, ***Po0.001 versus scramble control (Student's t-test).
pRetro-Super vector, downstream of the H1 promoter. For target gene overexpression, the ORFs encoding human RBL1, RBL2 and CASP8 were also cloned into the pRetro-Super vector, downstream of the CMV promoter. A scramble control pRetro-Super vector was also constructed at the same time. For retrovirus production, Plat-A cells were transfected with the above plasmids using the FuGENE HD transfection reagent (Roche, Penzberg, Upper Bavaria, Germany). The virus-containing supernatant was collected at 48 h after transfection, filtered to remove cell debris and used for the infection after titer quantification. The 3 0 -UTR of target genes was inserted into the pGL3 reporter vector. The mutation of the 3 0 -UTRs was performed by using the QuickChange Mutagenesis Kit (Agilent, Santa Clara, CA, USA).
Animal experiments
Female immunedeficient nude mice (BALB/C-nu), 5-week old, were purchased from the Shanghai Laboratory Animal Center (Chinese Academy of Sciences) and maintained in pathogen-free conditions. Protocols for animal experiments were approved by the Institutional Animal Care and Use Committee of the Changzhou NO.2 People's Hospital. U87 cells were infected by retroviruses expressing miR-106b-5p, shRNAs of target genes or the scramble control. After culturing for 48 h, the virus-mediated overexpression of miR-106b-5p or the knockdown of the targets was verified by QPCR or western blot analyses. A number of 5 Â 10 6 cells was injected subcutaneously into the back flanks of nude mice: each mouse was injected with scramble control into the left side and the miR-106b-5p or shRNA into the right side (six mice per group). Tumor size was monitored by measuring the length and the width using vernier calipers, and the tumor volume was calculated with the formula: (L Â W 2 ) Â 0.5 mm 3 , in which L is the length and W is the width of each tumor.
Microarray and QPCR
Total RNAs were collected from three glioma samples and three normal controls using TRIzol (Invitrogen) and the miRNeasy mini kit (QIAGEN, Hilden, Germany) according to the manufacturer's instructions. After having passed the RNA quantity measurement using the NanoDrop 1000, the RNA was used for miRNA microarray or QPCR analysis. For microarray analysis, the samples were labeled using the miRCURY Hy3/Hy5 Power labeling kit and hybridized on the miRCURY LNA Array (v.16.0). Following the washing steps, the slides were scanned using the Axon GenePix 4000B microarray scanner. Scanned images were then imported into GenePix Pro 6.0 software (Molecular devices, Sunnyvale, CA, USA) for grid alignment and data extraction. Replicated miRNAs were averaged and miRNAs whose intensities were X50 in all samples were chosen for calculating the normalization factor. Expressed data were normalized using the median normalization. After normalization, differentially expressed miRNAs were identified through Fold change filtering. Finally, the hierarchical clustering was performed to show the distinguishable miRNA expression profiling among samples. For miRNA QPCR analysis, mature miR-106b-5p was accurately quantified using the TaqMan MicroRNA Assay (4427975, ABI, Foster, CA, USA) according to the standard TaqMan MicroRNA Assay protocol, and U6 (4427975, ABI) was amplified as internal control. For mRNA QPCR analysis, cDNA was synthesized using Superscript III Reverse Transcriptase (Invitrogen) and random hexamers, QPCR was performed using the SYBR premix (ToneKer, Shanghai, China) using gene-specific primers and the housekeeping gene GAPDH was used as an internal control; the Tm value of all primers was set to 60 1C and the sequences were shown in Supplementary Table S2 .
Northern blot analysis
Total RNA was isolated from cells using the TRIzol reagent (Invitrogen). For northern blot analysis, total RNAs (20 mg) were separated on 15% denaturing polyacrylamide gels and then transferred to Hybond N þ nylon membrane (Qiagen). Following the UV cross-linking, the membrane was hybridized with the synthesized reverse and complementary oligonucleotides of miR-106b-5p or U6 labeled using biotin at 42 1C overnight. After washing twice in PBS and blocking in 10% (W/V) skim milk, membranes were incubated with Avidin-conjugated horseradish peroxidase and scanned with the Kodak scanner after the ECL reaction.
Cell proliferation and apoptosis
Cell proliferation was evaluated by the MTS assay and the focus formation assay. For MTS assay (Promega, Madison, WI, USA), U87 and LN-229 cells were seeded into 96-well plates at 4000 cells per well. After transfection and culture for different time, a volume of 10 ml of MTS was added into each well and the cells were incubated for additional 4 h, and then the optical density was measured at the wavelength of 490 nm. For the focus formation assay, after transfection, 200 viable cells were plated in six-well plates in triplicate and maintained in the complete medium for 10 days. Foci were fixed with 4% polyoxymethylene and stained with 0.1% crystal violet. For apoptosis analysis, cells were cultured in the six-well plates until they attained 60% confluent density. After transfection for 24h, the cell medium was changed to 0.2% FBS, cells were collected 48 h later and stained with Annexin V/Propidium Iodide staining kits (Invitrogen) and analyzed by the guava easyCyte Flow Cytometer (Millipore, Billerica, MA, USA).
Luciferase reporter assay HEK293T cells were maintained in DMEM and cells of 50% confluence in 24-well plates were transfected with 300 ng of the pGL3 luciferase reporter vector and 1 ng of the Renilla luciferase vector with the transfection reagent Lipofectamine 2000. Cell extracts were prepared 24 h after transfection, and the luciferase activity was measured with the DualLuciferase Reporter Assay system (Promega).
Western blotting
Total proteins were extracted from cell lines or tissue samples, and protein concentration was measured. Protein samples were fractionated using 12% polyacrylamide gels, transferred to PVDF membrane and blocked with 5% non-fat dairy milk in Tris-buffered saline (20 mM Tris and 150 mM NaCl, pH 7.4) with 0.05% Tween-20. Membranes were incubated with primary antibodies (Santa Cruz, Dallas, TX, USA) against human RBL1 (sc-318), RBL1 (sc-317), CASP8 (sc-56070) and GAPDH (sc-47778), followed by HRPconjugated secondary antibody and developed using the ECL reagent (Amersham, Little Chalfont, UK).
Statistics
All data are presented as the mean ± s.e.m. from at least three independent replicates. All statistical analyses were performed using Student's t-test. Differences were considered to be statistically significant at Po0.05.
